RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

BACKGROUND: Treatment options for patients with metastatic colorectal cancer (mCRC) include anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS wild-type tumours only and require prior mutation testing of “hot-spot” codons in exons 2, 3 and 4 of KRAS and NRA...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Cancer
Huvudupphovsmän: Boleij, Annemarie, Tack, Véronique, Taylor, Aliki, Kafatos, George, Jenkins-Anderson, Sophie, Tembuyser, Lien, Dequeker, Els, van Krieken, J. Han
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2016
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5080758/
https://ncbi.nlm.nih.gov/pubmed/27784278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2810-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk